<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="30161630-325a-4bb8-e063-6394a90a5e27"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">HIGHLIGHTS OF PRESCRIBING INFORMATION </content>
      <content styleCode="bold">These highlights do not include all the information needed to use FAMOTIDINE TABLETS safely and effectively. See full prescribing information for FAMOTIDINE TABLETS. </content>
      <br/>
      <br/>
      <br/>
      <br/>
      <content styleCode="bold">FAMOTIDINE tablets, for oral use
  <br/>
         <br/>
Initial U.S. Approval: 1986 
 </content>
   </title>
   <effectiveTime value="20250311"/>
   <setId root="f3abe0c2-2029-4d89-b413-606a421491e4"/>
   <versionNumber value="20"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="143213275"/>
            <name>Legacy Pharmaceutical Packaging, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="30164a77-b853-6278-e063-6394a90a5dea"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250311"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68645-140" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Famotidine</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Famotidine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0172-5728" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="SA1B764746" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5QZO15J2Z8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FAMOTIDINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5QZO15J2Z8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FAMOTIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68645-140-59" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20091026"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075511" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20091026"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="brown" xsi:type="CE">
                              <originalText>beige</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TEVA;5728</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_75834f76-a16e-4495-8017-4961b546a07b">
               <id root="b56ffb2f-6a47-4a52-e053-2a95a90a97ec"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). </paragraph>
                  <list listType="unordered">
                     <item>active gastric ulcer (GU). </item>
                     <item>active gastric ulcer (GU).</item>
                     <item>symptomatic nonerosive gastroesophageal reflux disease (GERD). </item>
                     <item>erosive esophagitis due to GERD, diagnosed by biopsy. </item>
                  </list>
                  <paragraph>Famotidine tablets are indicated in adults for the: </paragraph>
                  <list listType="unordered">
                     <item>treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). </item>
                     <item>reduction of the risk of duodenal ulcer recurrence. </item>
                  </list>
               </text>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Famotidine tablets are a histamine-2 (H2 ) receptor antagonist indicated (1): </paragraph>
                        <paragraph>In adult and pediatric patients 40 kg and greater for the treatment of: </paragraph>
                        <list listType="unordered">
                           <item>active duodenal ulcer (DU). </item>
                           <item>active gastric ulcer. </item>
                           <item>symptomatic nonerosive gastroesophageal reflux disease (GERD). </item>
                           <item>erosive esophagitis due to GERD, diagnosed by biopsy. </item>
                        </list>
                        <paragraph>In adults for the: </paragraph>
                        <list listType="unordered">
                           <item>treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). </item>
                           <item>reduction of the risk of DU recurrence. </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_385e3f73-0d67-4aa0-ae49-36913abb35b4">
               <id root="b56ffb2f-6a48-4a52-e053-2a95a90a97ec"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Indication </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Recommended Dosage (2.1)</content> 
           
   
      </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="italics">Adult and Pediatric Patients</content> 
           
   
      </td>
                                 <td>
                                    <content styleCode="italics">40 kg and greater</content> 
           
   
      </td>
                              </tr>
                              <tr>
                                 <td>Active DU </td>
                                 <td>
                                    <paragraph>40 mg once daily; or
             
     
        <br/>20 mg twice daily
            
    
       </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Active Gastric Ulcer </td>
                                 <td>40 mg once daily </td>
                              </tr>
                              <tr>
                                 <td>GERD </td>
                                 <td>20 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td>Erosive Esophagitis </td>
                                 <td>20 mg twice daily; or
            
    
       <br/>40 mg twice daily 
           
   
      </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="italics">Adults</content> 
           
   
      </td>
                                 <td> </td>
                              </tr>
                              <tr>
                                 <td>Pathological Hypersecretory Condition </td>
                                 <td>20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours </td>
                              </tr>
                              <tr>
                                 <td>Risk Reduction of DU Reoccurrence </td>
                                 <td>20 mg once daily </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. (2.1, 2.2) </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Administration (2.3): </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Take once daily before bedtime or twice daily in the morning and before bedtime with or without food. </item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_ffdb03f7-25bf-4c20-9b5b-8553a1435f53">
                     <id root="b56ffb2f-6a49-4a52-e053-2a95a90a97ec"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>Table 1 shows the recommended dosage of famotidine 20 mg and 40 mg tablets in adult and pediatric patients weighing 40 kg and greater with normal renal function. The use of famotidine 20 mg and 40 mg tablets is not recommended in pediatric patients weighing less than 40 kg because the lowest available strength (20 mg) exceeds the recommended dose for these patients
         
 
  <content styleCode="italics">. </content>Use another famotidine formulation for pediatric patients weighing less than 40 kg. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Recommended Dosage and Duration of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Normal Renal Function </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM1"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>a</sup> Both dosages demonstrated effectiveness in clinical trials 
         
 
  <content styleCode="italics">[see Clinical Studies (14)]</content>. 
        

 </paragraph>
                        <paragraph>
                           <sup>b</sup> In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4 weeks, consider an additional 2 to 4 weeks of treatment 
         
 
  <content styleCode="italics">[see Clinical Studies (14.1)]. </content>
                        </paragraph>
                        <paragraph>
                           <sup>c</sup> Longer treatment durations have not been studied in clinical trials 
         
 
  <content styleCode="italics">[see Clinical Studies (14.1, 14.2, 14.3)]</content>. 
        

 </paragraph>
                        <paragraph>
                           <sup>d</sup> In pediatric patients, the safety and effectiveness of famotidine tablets have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions 
         
 
  <content styleCode="italics">[see Use in Specific Populations (8.4)]</content>. 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Table 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_122b324f-2393-413a-b5be-a368b05e7224">
                     <id root="b56ffb2f-6a4a-4a52-e053-2a95a90a97ec"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Dosage in Renal Impairment</title>
                     <text>
                        <paragraph>Dosage adjustments of famotidine tablets are recommended for patients with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) 
         
 
  <content styleCode="italics">[see Use in Specific Populations (8.6)]</content>. Table 2 shows the recommended maximum dosage of famotidine 20 mg or 40 mg tablets for patients with renal impairment, by indication. Use the lowest effective dose. Some dosage adjustments may require switching to other formulations of famotidine (e.g., oral suspension, lower dose tablet). 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Recommended Maximum Dosage of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Moderate and Severe Renal Impairment </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM2"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>a</sup> An alternate dosage regimen is 10 mg once daily. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation. 
        

 </paragraph>
                        <paragraph>
                           <sup>b</sup> Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials 
         
 
  <content styleCode="italics">[see Clinical Studies (14.4)]</content>. 
        

 </paragraph>
                        <paragraph>
                           <sup>c</sup> In pediatric patients, the safety and effectiveness of famotidine tablets have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions 
         
 
  <content styleCode="italics">[see Use in Specific Populations (8.4)]</content>. 
        

 </paragraph>
                        <paragraph>
                           <sup>d</sup> Doses required to treat pathological hypersecretory conditions may exceed the maximum doses evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with famotidine tablets for pathological hypersecretory conditions is unknown. 
        

 </paragraph>
                        <paragraph>
                           <sup>e</sup> Recommended dosage regimen is 10 mg every other day. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation. 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Table 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0cdee28d-3d72-4945-ad7a-65d67e893c87">
                     <id root="b56ffb2f-6a4b-4a52-e053-2a95a90a97ec"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.3 Administration Instructions</title>
                     <text>
                        <list listType="unordered">
                           <item>Take famotidine tablets once daily before bedtime or twice daily in the morning and before bedtime, as recommended. </item>
                           <item>Famotidine tablets may be taken with or without food 
          
  
   <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. 
         
 
  </item>
                           <item>Famotidine tablets may be given with antacids. </item>
                        </list>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bb63d253-9656-4d9e-bbc7-0da009aa6921">
               <id root="eb8f13ae-c6a5-d7da-e053-2995a90af49c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>20 mg tablets: beige, round, unscored, film-coated tablets, debossed with "5728" on one side and "TEVA" on the other side.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 20 mg (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1447aafe-1ccb-47f3-8d38-178c416d43d7">
               <id root="b56ffb2f-6a4d-4a52-e053-2a95a90a97ec"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists. </paragraph>
               </text>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H2 receptor antagonists. (4) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0690388e-ce24-4243-af5f-eb30b93a8392">
               <id root="b56ffb2f-6a4e-4a52-e053-2a95a90a97ec"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Central Nervous System (CNS) Adverse Reactions:</content> Elderly patients and patients with renal impairment at increased risk; reduce the dosage. (2.2, 5.1, 8.5, 8.6) 
         
 
    </item>
                        </list>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">GI Malignancy:</content> Absence of GI symptoms does not preclude the presence of gastric malignancy; evaluate prior to initiating therapy. (5.2) 
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_be6df587-4aa9-46d7-9671-decd464cb224">
                     <id root="b56ffb2f-6a4f-4a52-e053-2a95a90a97ec"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.1 Central Nervous System Adverse Reactions</title>
                     <text>
                        <paragraph>Central nervous system (CNS) adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy, have been reported in elderly patients and patients with moderate and severe renal impairment treated with famotidine tablets. Since famotidine blood levels are higher in patients with renal impairment than in patients with normal renal function, dosage adjustments are recommended in patients with renal impairment 
         
 
  <content styleCode="italics">[see Dosage and Administration (2.2), Clinical Pharmacology (12.3)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c5d15787-4af6-4d97-8ed5-2b74e02e2398">
                     <id root="b56ffb2f-6a50-4a52-e053-2a95a90a97ec"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.2 Concurrent Gastric Malignancy</title>
                     <text>
                        <paragraph>In adults, symptomatic response to therapy with famotidine tablets does not preclude the presence of gastric malignancy. Consider evaluation for gastric malignancy in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with famotidine tablets. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_430c7b4f-eec4-48c2-8bd1-e386b7efb902">
               <id root="b56ffb2f-6a51-4a52-e053-2a95a90a97ec"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions are: headache, dizziness, constipation, and diarrhea. (6.1) </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3c9dae19-c859-4a6b-8343-21ef1fe88a65">
                     <id root="b56ffb2f-6a52-4a52-e053-2a95a90a97ec"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>6.1 
Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>Famotidine tablets was studied in 7 US and international placebo- and active-controlled trials in approximately 2500 patients 
         
 
  <content styleCode="italics">[see Clinical Studies (14)]</content>. A total of 1442 patients were treated with famotidine tablets, including 302 treated with 40 mg twice daily, 456 treated with 20 mg twice daily, 461 treated with 40 mg once daily, and 396 treated with 20 mg once daily. The population was 17-91 years old, fairly well distributed between gender and race; however, the predominant race treated was Caucasian. 
        

 </paragraph>
                        <paragraph>The following adverse reactions occurred in greater than or equal to 1% of famotidine tablets-treated patients: headache, dizziness and constipation. </paragraph>
                        <paragraph>The following other adverse reactions were reported in less than 1% of patients in clinical trials: </paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole: </content>fever, asthenia, fatigue 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular: </content>palpitations 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal: </content>elevated liver enzymes, vomiting, nausea, abdominal discomfort, anorexia, dry mouth 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic: </content>thrombocytopenia 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity: </content>orbital edema, rash, conjunctival injection, bronchospasm 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal: </content>musculoskeletal pain, arthralgia 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System/Psychiatric: </content>seizure, hallucinations, depression, anxiety, decreased libido, insomnia, somnolence 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin: </content>pruritus, dry skin, flushing 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses: </content>tinnitus, taste disorder 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Other: </content>impotence 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a4f6a8b9-5a5a-4afb-96a3-517f95adc260">
                     <id root="b56ffb2f-6a53-4a52-e053-2a95a90a97ec"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of famotidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular: </content>arrhythmia, AV block, prolonged QT interval 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal: </content>cholestatic jaundice, hepatitis 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic: </content>agranulocytosis, pancytopenia, leukopenia 
         
 
  <content styleCode="italics">Hypersensitivity: </content>anaphylaxis, angioedema, facial edema, urticaria 
         
 
  <content styleCode="italics">Musculoskeletal: </content>rhabdomyolysis, muscle cramps 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System/Psychiatric: </content>confusion, agitation, paresthesia 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory: </content>interstitial pneumonia 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin: </content>toxic epidermal necrolysis/Stevens-Johnson syndrome 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_be8cba1f-69d4-4143-94b4-6d2575df836f">
               <id root="b56ffb2f-6a54-4a52-e053-2a95a90a97ec"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drugs Dependent on Gastric pH for Absorption:</content> Systemic exposure of the concomitant drug may be significantly reduced leading to loss of efficacy. 
        

   </paragraph>
                        <paragraph>See full prescribing information for a list of interacting drugs. (7.1) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Tizanidine (CYP1A2) Substrate:</content> Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible. (7.2) 
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9b79d5c1-16e4-46dc-85ac-5451c559909c">
                     <id root="b56ffb2f-6a55-4a52-e053-2a95a90a97ec"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.1 Drugs Dependent on Gastric pH for Absorption</title>
                     <text>
                        <paragraph>Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug. </paragraph>
                        <paragraph>Concomitant administration of famotidine tablets with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir is not recommended. </paragraph>
                        <paragraph>See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, and rilpivirine. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f441e453-c9e8-422a-adcd-eb4902571cc7">
                     <id root="b56ffb2f-6a56-4a52-e053-2a95a90a97ec"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.2 Tizanidine (CYP1A2 Substrate)</title>
                     <text>
                        <paragraph>Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Avoid concomitant use with famotidine tablets. If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness. Refer to the full prescribing information for tizanidine. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_33fcf1b3-ae7a-4491-9578-9ae4d2e98295">
               <id root="b56ffb2f-6a57-4a52-e053-2a95a90a97ec"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20191226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Geriatric Use:</content> Use the lowest effective dose for an elderly patient and monitor renal function. (2.2, 5.1, 8.5) 
        

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal Impairment:</content> Risk of CNS adverse reactions and QT prolongation in patients with moderate and severe renal impairment; reduce the dosage. (2.2, 8.6) 
        

   </paragraph>
                        <paragraph>See 17 for Patient Counseling Information </paragraph>
                        <paragraph>
                           <content styleCode="bold">See 17 for PATIENT COUNSELING INFORMATION.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_91871271-d24a-43dd-a2fa-b773146026be">
                     <id root="b56ffb2f-6a58-4a52-e053-2a95a90a97ec"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Available data with H2-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis 
         
 
  <content styleCode="italics">(see Data)</content>. 
        

 </paragraph>
                        <paragraph>The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day, respectively, and in both species at intravenous doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine tablets. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (about 49 times the recommended human dose of 80 mg per day, based on body surface area) or higher. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_55d83b8c-c5f2-4bf5-b6d3-6bac9a002719">
                     <id root="b56ffb2f-6a59-4a52-e053-2a95a90a97ec"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There are limited data available on the presence of famotidine in human breast milk. There were no effects on the breastfed infant. There are no data on famotidine effects on milk production. Famotidine is present in the milk of lactating rats 
         
 
  <content styleCode="italics">(see Data)</content>. 
        

 </paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for famotidine and any potential adverse effects on the breastfed child from famotidine tablets or from the underlying maternal condition. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of famotidine at least 600 times the usual human dose. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_114d36c4-26b1-4dbc-83d5-44f7ea82c238">
                     <id root="b56ffb2f-6a5a-4a52-e053-2a95a90a97ec"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of famotidine tablets have been established in pediatric patients for the treatment of peptic ulcer disease (i.e., duodenal ulcer, gastric ulcer) and GERD (i.e., symptomatic nonerosive GERD, erosive esophagitis as diagnosed by endoscopy). The use of famotidine tablets and the recommended dosage of famotidine tablets in these pediatric patients is supported by evidence from adequate and well-controlled studies of famotidine tablets in adults and published pharmacokinetic and pharmacodynamic data in pediatric patients 
         
 
  <content styleCode="italics">[see Dosage and Administration (2.1), Clinical Pharmacology (12.2, 12.3)]</content>. In pediatric patients, the safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of duodenal ulcer recurrence have not been established. 
        

 </paragraph>
                        <paragraph>Famotidine 20 and 40 mg tablets are not recommended for use in pediatric patients weighing less than 40 kg because these tablet strengths exceed the recommended dose for these patients 
         
 
  <content styleCode="italics">[see Dosage and Administration (2.1)]</content>. For pediatric patients weighing less than 40 kg, consider another famotidine formulation (e.g., oral suspension, lower dose tablet). 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a62f6270-0836-4c31-ae19-cdca85990506">
                     <id root="b56ffb2f-6a5b-4a52-e053-2a95a90a97ec"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 1442 famotidine tablets-treated patients in clinical studies, approximately 10% were 65 and older. In these studies, no overall differences in safety or effectiveness were observed between elderly and younger patients. In postmarketing experience, CNS adverse reactions have been reported in elderly patients with and without renal impairment receiving famotidine tablets 
         
 
  <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. 
        

 </paragraph>
                        <paragraph>Famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to famotidine tablets may be greater in elderly patients, particularly those with impaired renal function 
         
 
  <content styleCode="italics">[see Use in Specific Populations (8.6)]</content>. 
        

 </paragraph>
                        <paragraph>In general, use the lowest effective dose of famotidine tablets for an elderly patient and monitor renal function 
         
 
  <content styleCode="italics">[see Dosage and Administration (2.2)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6cfb3296-cad1-4e41-ae3d-a4c0373cc868">
                     <id root="b56ffb2f-6a5c-4a52-e053-2a95a90a97ec"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>CNS adverse reactions and prolonged QT intervals have been reported in patients with moderate and severe renal impairment 
         
 
  <content styleCode="italics">[see Warnings and Precautions (5.1)]. </content>The clearance of famotidine is reduced in adults with moderate and severe renal impairment compared to adults with normal renal function 
         
 
  <content styleCode="italics">[see Clinical Pharmacology (12.3)]. </content>No dosage adjustment is needed in patients with mild renal impairment (creatinine clearance greater than or equal to 60 mL/minute). Dosage reduction is recommended in adult and pediatric patients greater than or equal to 40 kg with moderate or severe renal impairment (creatinine clearance less than 60 mL/minute) 
         
 
  <content styleCode="italics">[see Dosage and Administration (2.2)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_235c62b4-b267-44e3-a7e4-3ef4e54eebdc">
               <id root="b56ffb2f-6a5d-4a52-e053-2a95a90a97ec"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The types of adverse reactions in overdosage of famotidine tablets are similar to the adverse reactions encountered with use of recommended dosages 
       
 
  <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. 
      

 </paragraph>
                  <paragraph>In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed. </paragraph>
                  <paragraph>Due to low binding to plasma proteins, famotidine is eliminated by hemodialysis. There is limited experience on the usefulness of hemodialysis as a treatment for famotidine tablets overdosage. </paragraph>
               </text>
               <effectiveTime value="20191226"/>
            </section>
         </component>
         <component>
            <section ID="LINK_15396a40-2918-4c9f-bda9-9784e2b861c1">
               <id root="b56ffb2f-6a5e-4a52-e053-2a95a90a97ec"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>The active ingredient in Famotidine Tablets USP is a histamine-2 (H2) receptor antagonist. Famotidine, USP is [1-Amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio] propylidene] sulfamide and has the following structural formula: </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>Each Famotidine Tablet USP for oral administration contains either 20 mg or 40 mg of famotidine, USP and has the following inactive ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized corn starch, sodium starch glycolate, talc, titanium dioxide, yellow iron oxide. In addition, the 20 mg contains lactose monohydrate, red iron oxide and triacetin and the 40 mg contains FD&amp;C blue No. 2 aluminum lake and FD&amp;C yellow No. 6 aluminum lake. </paragraph>
                  <paragraph>Famotidine, USP is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol. </paragraph>
               </text>
               <effectiveTime value="20191226"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="famotidine-tablets---teva-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1d793e7c-fae0-4017-abd1-e30eb0ffc365">
               <id root="b56ffb2f-6a5f-4a52-e053-2a95a90a97ec"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20191226"/>
               <component>
                  <section ID="LINK_3259f8d4-2855-40a5-8975-e56f14c3bc20">
                     <id root="b56ffb2f-6a60-4a52-e053-2a95a90a97ec"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Famotidine is a competitive inhibitor of histamine-2 (H2) receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c70f1ee1-6c41-44e9-91ab-4442d87df8ba">
                     <id root="b56ffb2f-6a61-4a52-e053-2a95a90a97ec"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults </content>
                        </paragraph>
                        <paragraph>Famotidine inhibited both basal and nocturnal gastric secretion, as well as secretion stimulated by food and pentagastrin. After oral administration of famotidine tablets, the onset of the antisecretory effect occurred within one hour; the maximum effect was dose-dependent, occurring within one to three hours. Duration of inhibition of secretion by doses of 20 mg and 40 mg was 10 to 12 hours. </paragraph>
                        <paragraph>Single evening oral doses of 20 mg and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours. The same doses given in the morning suppressed food-stimulated acid secretion in all subjects. The mean suppression was 76% and 84%, respectively, 3 to 5 hours after administration, and 25% and 30%, respectively, 8 to 10 hours after administration. In some subjects who received the 20 mg dose, however, the antisecretory effect was dissipated within 6 to 8 hours. There was no cumulative effect with repeated doses. The nocturnal intragastric pH was raised by evening doses of 20 mg and 40 mg of famotidine tablets to mean values of 5.0 and 6.4, respectively. When famotidine tablets was given after breakfast, the basal daytime interdigestive pH at 3 and 8 hours after 20 mg or 40 mg of famotidine was raised to about 5. </paragraph>
                        <paragraph>Famotidine had little or no effect on fasting or postprandial serum gastrin levels. Gastric emptying and exocrine pancreatic function were not affected by famotidine tablets. </paragraph>
                        <paragraph>In clinical pharmacology studies, systemic effects of famotidine in the CNS, cardiovascular, respiratory or endocrine systems were not noted. Also, no anti-androgenic effects were noted. Serum hormone levels, including prolactin, cortisol, thyroxine (T4), and testosterone, were not altered after treatment with famotidine. </paragraph>
                        <paragraph>Pediatric Patients </paragraph>
                        <paragraph>Pharmacodynamics of famotidine, assessed by gastric pH, were evaluated in 5 pediatric patients 2 to 13 years of age using the sigmoid Emax model. These data suggest that the relationship between serum concentration of famotidine and gastric acid suppression is similar to that observed in adults (see Table 3). </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3: Serum Concentrations of Famotidine Associated with Gastric Acid Reduction in Famotidine Tablets-Treated Pediatric and Adult Patients</content>
                           <content styleCode="bold">
                              <sup>a </sup>
                           </content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM4"/>
                        <paragraph>
                           <sup>a </sup>Using the Sigmoid Emax model, serum concentrations of famotidine associated with 50% maximum gastric acid reduction are presented as means ± SD. 
        

 </paragraph>
                        <paragraph>In a study examining the effect of famotidine on gastric pH and duration of acid suppression in pediatric patients, four pediatric patients ages 11 to 15 years of age using the oral formulation at a dose of 0.5 mg/kg, maintained a gastric pH above 5 for 13.5 ± 1.8 hours. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                     <component>
                        <observationMedia ID="MM4">
                           <text>Table 3</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2a8cad23-1ea6-459c-8286-1f752bb13a50">
                     <id root="b56ffb2f-6a62-4a52-e053-2a95a90a97ec"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption </content>
                        </paragraph>
                        <paragraph>Famotidine is incompletely absorbed. The bioavailability of oral doses is 40 to 45%. Bioavailability may be slightly increased by food, or slightly decreased by antacids; however, these effects are of no clinical consequence. </paragraph>
                        <paragraph>Peak famotidine plasma levels occur in 1 to 3 hours. Plasma levels after multiple dosages are similar to those after single doses. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution </content>
                        </paragraph>
                        <paragraph>Fifteen to 20% of famotidine in plasma is protein bound. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism </content>
                        </paragraph>
                        <paragraph>Famotidine undergoes minimal first-pass metabolism. Twenty-five to 30% of an oral dose was recovered in the urine as unchanged compound. The only metabolite identified in humans is the S-oxide. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion </content>
                        </paragraph>
                        <paragraph>Famotidine has an elimination half-life of 2.5 to 3.5 hours. Famotidine is eliminated by renal (65 to 70%) and metabolic (30 to 35%) routes. Renal clearance is 250 to 450 mL/minute, indicating some tubular excretion. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients </content>
                        </paragraph>
                        <paragraph>Bioavailability studies of 8 pediatric patients (11 to 15 years of age) showed a mean oral bioavailability of 0.5 compared to adult values of 0.42 to 0.49. Oral doses of 0.5 mg per kg achieved AUCs of 580 ± 60 ng•hr/mL in pediatric patients 11 to 15 years of age, compared to 482 ± 181 ng•hr/mL in adults treated with 40 mg orally. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment </content>
                        </paragraph>
                        <paragraph>In adult patients with severe renal impairment (creatinine clearance less than 30 mL/minute), the systemic exposure (AUC) of famotidine increased at least 5-fold. In patients with moderate renal impairment (creatinine clearance between 30 to 60 mL/minute), the AUC of famotidine increased at least 2-fold 
         
 
  <content styleCode="italics">[see Dosage and Administration (2.2), Use in Specific Population (8.6)]</content>.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Organic Anion Transporter (OAT) 1 and 3: In vitro </content>studies indicate that famotidine is a substrate for OAT1 and OAT3. Following coadministration of probenecid (1500 mg), an inhibitor of OAT1 and OAT3, with a single oral 20 mg dose of famotidine in 8 healthy subjects, the serum AUC0-10h of famotidine increased from 424 to 768 ng•hr/mL and the maximum serum concentration (Cmax) increased from 73 to 113 ng/mL. Renal clearance, urinary excretion rate and amount of famotidine excreted unchanged in urine were decreased. The clinical relevance of this interaction is unknown. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Multidrug and Toxin Extrusion Protein 1 (MATE-1): </content>An 
         
 
  <content styleCode="italics">in vitro </content>study showed that famotidine is an inhibitor of MATE-1. However, no clinically significant interaction with metformin, a substrate for MATE-1, was observed. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">CYP1A2: </content>Famotidine is a weak CYP1A2 inhibitor. 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_6237b4a5-7bdc-4d20-b75e-13c02eebfd1b">
               <id root="b56ffb2f-6a63-4a52-e053-2a95a90a97ec"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20191226"/>
               <component>
                  <section ID="LINK_7739e7a2-c9d1-4b32-80dc-8f2efa5e4109">
                     <id root="b56ffb2f-6a64-4a52-e053-2a95a90a97ec"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenic potential of famotidine was assessed in a 106-week oral carcinogenicity study in rats and a 92-week oral carcinogenicity study in mice. In the 106-week study in rats and the 92-week study in mice at oral doses of up to 2000 mg/kg/day (approximately 243 and 122 times, respectively, based on body surface area, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis), there was no evidence of carcinogenic potential for famotidine. </paragraph>
                        <paragraph>Famotidine was negative in the microbial mutagen test (Ames test) using 
         
 
  <content styleCode="italics">Salmonella typhimurium </content>and 
         
 
  <content styleCode="italics">Escherichia coli </content>with or without rat liver enzyme activation at concentrations up to 10,000 mcg/plate. In 
         
 
  <content styleCode="italics">in vivo </content>studies in mice, with a micronucleus test and a chromosomal aberration test, no evidence of a mutagenic effect was observed. 
        

 </paragraph>
                        <paragraph>In studies with rats given oral doses of up to 2000 mg/kg/day (approximately 243 times, based on body surface area, the recommended human dose of 80 mg per day) fertility and reproductive performance were not affected. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4fffb39b-bfc2-4375-9e39-2518550f4db6">
               <id root="b56ffb2f-6a65-4a52-e053-2a95a90a97ec"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20191226"/>
               <component>
                  <section ID="LINK_fe0e55da-a428-43ed-9eff-47c5d99b1bd1">
                     <id root="b56ffb2f-6a66-4a52-e053-2a95a90a97ec"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.1 Active Duodenal Ulcer</title>
                     <text>
                        <paragraph>In a U.S. multicenter, double-blind trial in adult outpatients with endoscopically confirmed duodenal ulcer (DU), orally administered famotidine was compared to placebo. As shown in Table 4, 70% of patients treated with famotidine 40 mg at bedtime were healed by Week 4. Most patients’ DU healed within 4 weeks. </paragraph>
                        <paragraph>Patients not healed by Week 4 were continued in the trial. By Week 8, 83% of patients treated with famotidine tablets had healed DU, compared to 45% of patients treated with placebo. The incidence of DU healing with famotidine tablets was greater than with placebo at each time point based on proportion of endoscopically confirmed healed DUs. Trials have not assessed the safety of famotidine tablets in uncomplicated active DU for periods of more than 8 weeks. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4: Patients with Endoscopically Confirmed Healed Duodenal Ulcers </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM5"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>a </sup>p&lt;0.001 vs. placebo 
        

 </paragraph>
                        <paragraph>In this study, time to relief of daytime and nocturnal pain was shorter for patients receiving famotidine than for patients receiving placebo; patients receiving famotidine also took less antacid than patients receiving placebo. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                     <component>
                        <observationMedia ID="MM5">
                           <text>Table 4</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-5.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_63a3748d-3b63-48c3-ac0e-1a6dacef969b">
                     <id root="b56ffb2f-6a67-4a52-e053-2a95a90a97ec"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.2 Active Gastric Ulcer</title>
                     <text>
                        <paragraph>In both a U.S. and an international multicenter, double-blind trials in patients with endoscopically confirmed active gastric ulcer (GU), orally administered famotidine 40 mg at bedtime was compared to placebo. Antacids were permitted during the trials, but consumption was not significantly different between the famotidine and placebo groups. </paragraph>
                        <paragraph>As shown in Table 5, the incidence of GU healing confirmed by endoscopy (dropouts counted as unhealed) with famotidine was greater than placebo at Weeks 6 and 8 in the U.S. trial, and at Weeks 4, 6 and 8 in the international trial. In these trials, most famotidine tablets-treated patients healed within 6 weeks. Trials have not assessed the safety of famotidine tablets in uncomplicated active GU for periods of more than 8 weeks. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 5: Patients with Endoscopically Confirmed Healed Gastric Ulcers </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM6"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>a </sup>p≤0.01 vs. placebo 
        

 </paragraph>
                        <paragraph>
                           <sup>b </sup>p≤0.05 vs. placebo 
        

 </paragraph>
                        <paragraph>Time to complete relief of daytime and nighttime pain was statistically significantly shorter for patients receiving famotidine than for patients receiving placebo; however, neither trial demonstrated a statistically significant difference in the proportion of patients whose pain was relieved by the end of the trial (Week 8). </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                     <component>
                        <observationMedia ID="MM6">
                           <text>Table 5</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-6.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_17c55553-7885-43bd-846d-d295b08a4a5d">
                     <id root="b56ffb2f-6a68-4a52-e053-2a95a90a97ec"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.3 Symptomatic Gastroesophageal Reflux Disease (GERD)</title>
                     <text>
                        <paragraph>Orally administered famotidine was compared to placebo in a U.S. trial that enrolled patients with symptoms of GERD and without endoscopic evidence of esophageal erosion or ulceration. As shown in Table 6, patients treated with famotidine 20 mg twice daily had greater improvement in symptomatic GERD than patients treated with 40 mg at bedtime or placebo. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 6: Patients with Improvement of Symptomatic GERD (N=376) </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM7"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>a </sup>p≤0.01 vs. placebo 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                     <component>
                        <observationMedia ID="MM7">
                           <text>Table 6</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-7.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f116fbe0-b19a-4069-9b5b-3bf3913344b4">
                     <id root="b56ffb2f-6a69-4a52-e053-2a95a90a97ec"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.4 Erosive Esophagitis due to GERD</title>
                     <text>
                        <paragraph>Healing of endoscopically verified erosion and symptomatic improvement were studied in a U.S. and an international double-blind trial. Healing was defined as complete resolution of all erosions visible with endoscopy. The U.S. trial comparing orally administered famotidine 40 mg twice daily to placebo and orally administered famotidine 20 mg twice daily showed a significantly greater percentage of healing of erosive esophagitis for famotidine 40 mg twice daily at Weeks 6 and 12 (Table 7). </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 7: Patients with Endoscopic Healing of Erosive Esophagitis - U.S. Study (N=318) </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM8"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>a </sup>p≤0.01 vs. placebo 
        

 </paragraph>
                        <paragraph>
                           <sup>b </sup>p≤0.01 vs. famotidine 20 mg twice daily 
        

 </paragraph>
                        <paragraph>
                           <sup>c </sup>p≤0.05 vs. famotidine 20 mg twice daily 
        

 </paragraph>
                        <paragraph>As compared to placebo, patients in the U.S. trial who received famotidine had faster relief of daytime and nighttime heartburn, and a greater percentage of famotidine tablets-treated patients experienced complete relief of nighttime heartburn. These differences were statistically significant. </paragraph>
                        <paragraph>In the international trial, when orally administered famotidine 40 mg twice daily was compared to orally administered ranitidine 150 mg twice daily, a statistically significantly greater percentage of healing of erosive esophagitis was observed with famotidine 40 mg twice daily at Week 12 (Table 8). There was, however, no significant difference in symptom relief among treatment groups. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 8: Patients with Endoscopic Healing of Erosive Esophagitis - International Study (N=440) </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM9"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>a </sup>p≤0.05 vs ranitidine 150 mg twice daily 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                     <component>
                        <observationMedia ID="MM8">
                           <text>Table 7</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-8.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM9">
                           <text>Table 8</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="famotidine-tablets---teva-9.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_534b6a21-b273-4c7e-a1af-722aeeb91e24">
                     <id root="b56ffb2f-6a6a-4a52-e053-2a95a90a97ec"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.5 Pathological Hypersecretory Conditions</title>
                     <text>
                        <paragraph>In trials of patients with pathological hypersecretory conditions such as Zollinger-Ellison syndrome with or without multiple endocrine neoplasias, famotidine significantly inhibited gastric acid secretion and controlled associated symptoms. Orally administered famotidine dosages from 20 mg to 160 mg every 6 hours maintained basal acid secretion below 10 mEq/hour; initial dosages were titrated to the individual patient need and subsequent adjustments were necessary with time in some patients. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fdd3340f-d4b4-445c-814e-dba39c87b36e">
                     <id root="b56ffb2f-6a6b-4a52-e053-2a95a90a97ec"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.6 Risk Reduction of Duodenal Ulcer Recurrence</title>
                     <text>
                        <paragraph>Two randomized, double-blind, multicenter trials in patients with endoscopically confirmed healed DUs demonstrated that patients receiving treatment with orally administered famotidine 20 mg at bedtime had lower rates of DU recurrence, as compared with placebo. </paragraph>
                        <list listType="unordered">
                           <item>In the U.S. trial, DU recurrence within 12 months was 2.4 times greater in patients treated with placebo than in the patients treated with famotidine. The 89 famotidine tablets-treated patients had a cumulative observed DU recurrence rate of 23%, compared to a 57% in the 89 patients receiving placebo (p&lt;0.01). </item>
                        </list>
                        <list listType="unordered">
                           <item>In the international trial, the cumulative observed DU recurrence within 12 months in the 307 famotidine tablets-treated patients was 36%, compared to 76% in the 325 patients who received placebo (p&lt;0.01). </item>
                        </list>
                        <paragraph>Controlled trials have not extended beyond one year. </paragraph>
                     </text>
                     <effectiveTime value="20191226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b4874083-dd8d-4b8f-8989-674d9209929e">
               <id root="eb8f1433-f892-d07e-e053-2995a90a110e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED</title>
               <text>
                  <paragraph>Famotidine Tablets USP, 20 mg are available as beige, round, unscored, film-coated tablets, debossed with "5728" on one side and “TEVA” on the other side containing 20 mg famotidine, packaged in bottles of 60 tablets.</paragraph>
                  <paragraph>Bottles of 60: 20 mg (NDC 68645-140-59)</paragraph>
                  <paragraph/>
                  <paragraph>Dispense in a well-closed, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Avoid storage of famotidine tablets at temperatures above 40°C (104°F).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20191226"/>
            </section>
         </component>
         <component>
            <section ID="LINK_72f448b7-1059-4469-861e-1ab95a8da0d6">
               <id root="b56ffb2f-6a6d-4a52-e053-2a95a90a97ec"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Central Nervous System (CNS) Adverse Reactions </content>
                  </paragraph>
                  <paragraph>Advise elderly patients and those with moderate and severe renal impairment of the risk of CNS adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy 
       
 
  <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. Report symptoms immediately to a healthcare provider. 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">QT Prolongation </content>
                  </paragraph>
                  <paragraph>Advise patients with moderate and severe renal impairment of the risk of QT interval prolongation 
       
 
  <content styleCode="italics">[see Use in Specific Populations (8.6)]</content>. Report new cardiac symptoms, such as palpitations, fainting and dizziness or lightheadedness immediately to a healthcare provider. 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration </content>
                  </paragraph>
                  <paragraph>Advise patients: </paragraph>
                  <list listType="unordered">
                     <item>Take famotidine tablets once daily before bedtime or twice daily in the morning and before bedtime, as recommended. </item>
                     <item>Famotidine tablets may be taken with or without food. </item>
                     <item>Famotidine tablets may be given with antacids. </item>
                  </list>
                  <paragraph>Manufactured In Croatia By: 
       
 
  <br/>
                     <content styleCode="bold">PLIVA HRVATSKA d.o.o.</content>
                     <br/>Zagreb, Croatia
      

 </paragraph>
                  <paragraph>Manufactured For:
       
 
  <br/>TEVA PHARMACEUTICALS USA, Inc.
       
 
  <br/>North Wales, PA 19454
      

 </paragraph>
                  <paragraph>Rev. F 1/2019</paragraph>
                  <paragraph>Distributed by:
       
 
  <br/>
                     <content styleCode="bold">WAL-MART</content>
                     <br/>Bentonville, AR 72716
      

 </paragraph>
                  <paragraph>Packaged by:
       
 
  <br/>
                     <content styleCode="bold">LEGACY PHARMACEUTICAL PACKAGING LLC</content>
                     <br/>Earth City, MO 63045
      

 </paragraph>
               </text>
               <effectiveTime value="20191226"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4bf9e1db-50b4-4bf7-956e-54dbc4438ba0">
               <id root="eb8f2f16-840d-7195-e053-2995a90ae090"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM10"/>
                  </paragraph>
               </text>
               <effectiveTime value="20191226"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>Famotidine Tablets USP 20 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="famotidine-tablets---teva-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>